Multinational phase 1-2 study of epcoritamab for relapsed or refractory B-cell non-Hodgkin lymphoma
Dr. Martin Hutchings
Patients with relapsed or refractory B-cell non-Hodgkin lymphoma have few treatment options. Epcoritamab is a novel bispecific antibody that targets CD3 and CD20 and induces T-cell-mediated cytotoxic activity against CD20+ malignant B-cells. A multinational phase 1-2 study found tolerability and promising activity of single-agent epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
